Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Go Vida Plena vs Tell Her Doc

Go Vida Plena
Graded #151

Higher grade

vs+10.800000000000004
Tell Her Doc
Graded #400

Lower grade

The verdict

Go Vida Plena takes it — 68.2/100 to 57.4/100.

Go Vida Plena grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Go Vida Plena is a Spanish-first, Latino-focused medical weight-loss program offering GLP-1 therapy from $199/month, based in Utah.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGo Vida Plena +26
54
28
Dose & formulationGo Vida Plena +12
75
63
Clinical oversightGo Vida Plena +7
83
76
Labs & monitoringGo Vida Plena +11
63
52
FulfillmentTell Her Doc +6
77
83
Contract termsTell Her Doc +6
55
61
Go Vida Plena · left barTell Her Doc · right bar

The numbers

MetricGo Vida PlenaTell Her Doc
WeighScore68.2/10057.4/100
GradeCC
Scorecard rank#151#400
Semaglutide$199/mo (starting dose, compounded)$269/mo (microdose tier, plus a separate fee, compounded)
Tirzepatide$269/mo (starting dose, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Go Vida Plena

Graded #151 · C

Strengths

  • Spanish-first, fully bilingual GLP-1 program tailored to Latino food and lifestyle - a genuinely underserved niche
  • Compounded semaglutide, tirzepatide, and oral semaglutide from $199/mo, with installment pay (Klarna, Afterpay, Affirm)
  • Free initial consultation; medications shipped discreetly to your door after a medical evaluation
  • Includes 24/7 support, 4 virtual visits a year, and ongoing nutrition coaching
  • Physician-supervised program (Utah medical backing) with continuous follow-up

Where it loses points

  • Utah-based, and the full list of states served is not published
  • Only a '$199/mo starting' price is shown upfront; tirzepatide and oral-semaglutide pricing isn't published
  • The compounding pharmacy is not named (a 'provider pharmacies' page exists but lists no name)
  • Compounded GLP-1 medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • No LegitScript certification displayed
Tell Her Doc

Graded #400 · C

Strengths

  • Full compounded GLP-1 lineup — semaglutide and tirzepatide in injection, oral and orally-dissolving-tablet forms, plus microdoses
  • Names its compounding pharmacy partner (Casa Pharma RX), which is independently listed in our pharmacy registry
  • No monthly membership, cancel anytime, free discreet shipping; HSA/FSA eligible with buy-now-pay-later plans
  • Serves patients in all 50 states via a private online consultation

Where it loses points

  • 'All sales are final' — no refunds once medication has left the pharmacy
  • Exact price is plan-dependent, shown after you pick a product; advertised 'starting at $269', with a lower $140 intro on oral semaglutide
  • References LegitScript but without an independently verifiable seal — we couldn't confirm certification
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard